Tuberculosis — metabolism and respiration in the absence of growth
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Human tuberculosis is a complex disease caused by bacterial populations that are located in discrete lesions (microenvironments) in a single host. Some of these microenvironments are conducive to replication, whereas others restrict bacterial growth without necessarily sterilizing the infecting microorganisms. The physical and biochemical milieu in these lesions is poorly defined. None of the existing animal models for tuberculosis (except perhaps non-human primates) reproduce the diversity of disease progression that is seen in humans. Nonetheless, transcriptomics and studies using bacterial mutants have led to testable hypotheses about metabolic functions that are essential for viability in the absence of replication. A complete picture of bacterial metabolism must balance reducing equivalents while maintaining an energized membrane and basic cellular processes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“M. tuberculosis harbours genes for a cytochrome c pathway consisting of a menaquinol-cytochrome c oxidoreductase termed the bc1 complex (encoded by the qcrCAB operon, complex III) and an aa3-type cytochrome c oxidase (encoded by the genes ctaBCDE, complex IV) belonging to the heme-copper respiratory oxidase family (69–71) (Table 1).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [69]
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847 · cited 1×
“tuberculosis encodes four glucose-6-phosphate dehydrogenases — two of which require NADPH as the electron donor ( zwf1 , zwf2 ), whereas fgd1 and fgd2 encode F 420 -requiring dehydrogenase”
BackgroundSelf-citationExploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“However, tumour cells are able to adjust their metabolism to adapt to anaerobic condition”
BackgroundThe Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
Genes required for mycobacterial growth defined by high density mutagenesis
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03425.x · Cited by 2,544
Nathan, C., & Shiloh, M. U. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.16.8841 · Cited by 1,469 · cited 1×
“3 ), whereas higher concentrations might reach other sensitive intracellular target”
BackgroundTranscriptional Adaptation of Mycobacterium tuberculosis within Macrophages
Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030846 · Cited by 1,420
Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., & Duncan, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02779.x · Cited by 1,395
McKinney, J. D., zu Bentrup, K. H., Muñoz-Elías, E. J., Miczak, A., Chen, B., Chan, W.-T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., & Russell, D. G. (2000) · Nature · doi:10.1038/35021074 · Cited by 1,360
Identification of nitric oxide synthase as a protective locus against tuberculosis
MacMicking, J. D., North, R. J., LaCourse, R., Mudgett, J. S., Shah, S. K., & Nathan, C. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5243 · Cited by 1,180 · cited 1×
“tuberculosis during the chronic stage of the disease in mice is largely dependent on production of nitric oxide and other REACTIVE NITROGEN INTERMEDIATES (RNI), with decreased production of RNIs leading to reactivation of diseas”
BackgroundWayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
Research works printed but not linked: 4
- Jagirdar, J. & Zagzag, D. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 323–344 (Lippincott Williams & Wilkins, Philadelphia, 2004). A good current and historical overview of the pathology of different forms of tuberculosis in humans.
- Daley, C. L. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 85–99 (Lippincott Williams & Wilkins, Philadelphia, 2004).
- Condos, R. & Rom, W. N. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 285–299 (Lippincott Williams & Wilkins, Philadelphia, 2004).
- Garay, S. M. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 345–394 (Lippincott Williams & Wilkins, Philadelphia, 2004). A review of the clinical aspects of pulmonary tuberculosis with well-documented case studies of reactivation disease.
Cited by
Items 101–200 of 452
Johnston, J. B., Ouellet, H., & de Montellano, P. R. O. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.161117 · Cited by 108
Yokoyama, K., & Lilla, E. A. (2018) · Natural Product Reports · doi:10.1039/c8np00006a · Cited by 105
Tan, M. P., Sequeira, P., Lin, W. W., Phong, W. Y., Cliff, P., Ng, S. H., Lee, B. H., Camacho, L., Schnappinger, D., Ehrt, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013356 · Cited by 101
Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis
Lee, B. S., Hards, K., Engelhart, C. A., Hasenoehrl, E. J., Kalia, N. P., Mackenzie, J. S., Sviriaeva, E., Chong, S. M. S., Manimekalai, M. S. S., Koh, V. H., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013207 · Cited by 97
“This uniquely long therapy is believed to be due to a persistent subpopulation of bacteria which is able to survive for extended periods of time without growth, and is tolerant to the first-line drugs (Dick, 2001; Wayne & Sohaskey, 2001; Betts et al, 2002; Boshoff & Barry, 2005).”
BackgroundInfluentialUnderstanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies
Esmail, H., Barry, C. E., & Wilkinson, R. J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.013 · Cited by 108
“One of the primary difficulties encountered by the bacillus in adapting to hypoxia is in disposing of excess reducing equivalents generated by both anabolic and catabolic processes [52].”
BackgroundSelf-citationProfiling the Proteome of Mycobacterium tuberculosis during Dormancy and Reactivation
Gopinath, V., Raghunandanan, S., Gomez, R. L., Jose, L., Surendran, A., Ramachandran, R., Pushparajan, A. R., Mundayoor, S., Jaleel, A., & Kumar, R. A. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.051151 · Cited by 100
Discovery of novel isoxazolines as anti-tuberculosis agents
Tangallapally, R. P., Sun, D., Rakesh, R., Budha, N. R., Lee, R. B., Lenaerts, A. J. M., Meibohm, B., & Lee, R. E. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.048 · Cited by 96
Dormant forms of Mycobacterium smegmatis with distinct morphology
Anuchin, A. M., Mulyukin, A. L., Сузина, Н. Е., Дуда, В. И., El-Registan, G. I., & Kaprelyants, A. S. (2009) · Microbiology · doi:10.1099/mic.0.023028-0 · Cited by 96
“In recent years, significant progress has been achieved in characterization of various aspects of mycobacterial infection and adaptation to different environmental conditions (Young et al., 2005; Boshoff & Barry, 2005).”
BackgroundReece, S. T., Loddenkemper, C., Askew, D. J., Zedler, U., Schommer-Leitner, S., Stein, M., Mir, F. A., Dorhoi, A., Mollenkopf, H., Silverman, G. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42796 · Cited by 96
Pecsi, I., Hards, K., Ekanayaka, N., Berney, M., Hartman, T., Jacobs, W. R., & Cook, G. M. (2014) · mBio · doi:10.1128/mbio.01093-14 · Cited by 92
“Succinate oxidation to fumarate results in the generation of MQH2, which is then used by either the proton-pumping MQH2cytochrome c oxidoreductase bc1-aa3-type cytochrome c oxidase (bc1-aa3 pathway) and/or non-proton-translocating cytochrome bd-type MQH2 oxidase (1, 2).”
BackgroundStreptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis
Zhang, M., Sala, C., Hartkoorn, R. C., Dhar, N., Mendoza-Losana, A., & Cole, S. T. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01125-12 · Cited by 99
“The pathogen can enter a dormant or latent state characterized by limited growth and metabolism and, most importantly, by phenotypic resistance to the commonly used medications (8, 10), thereby allowing indefinite persistence in the human body.”
BackgroundBashiri, G., Squire, C. J., Moreland, N. J., & Baker, E. N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801854200 · Cited by 106
Pyrimidine Salvage Pathway in Mycobacterium tuberculosis
Villela, A. D., Sánchez-Quitian, Z. A., Ducati, R. G., Santos, D. S., & Basso, L. A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795029555 · Cited by 94
Mao, J., Wang, Y., Wan, B., Kozikowski, A. P., & Franzblau, S. G. (2007) · ChemMedChem · doi:10.1002/cmdc.200700112 · Cited by 87
Respiratory ATP synthesis: the new generation of mycobacterial drug targets?
Bald, D., & Koul, A. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.01959.x · Cited by 94
Prosser, G. A., Brandenburg, J., Reiling, N., Barry, C. E., Wilkinson, R. J., & Wilkinson, K. A. (2016) · Microbes and Infection · doi:10.1016/j.micinf.2016.10.001 · Cited by 100
“In these characteristic lesions, mycobacteria often reside within necrotic tissue that has no obvious supply of oxygen [91].”
BackgroundSelf-citationStrain specific transcriptional response in Mycobacterium tuberculosis infected macrophages
Koo, M.-S., Subbian, S., & Kaplan, G. (2012) · Cell Communication and Signaling · doi:10.1186/1478-811x-10-2 · Cited by 98
“Aerosolized Mtb, once inhaled into the lung and internalized by alveolar macrophages can induce phagocyte activation leading to control of bacillary growth and establishment of a state of nonreplicating persistence [1-3].”
The complex architecture of mycobacterial promoters
Newton-Foot, M., & van Pittius, N. C. G. (2012) · Tuberculosis · doi:10.1016/j.tube.2012.08.003 · Cited by 97
Noncognate Mycobacterium tuberculosis Toxin-Antitoxins Can Physically and Functionally Interact
Zhu, L., Sharp, J. D., Kobayashi, H., Woychik, N. A., & Inouye, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.163105 · Cited by 97
Ehlers, S. (2009) · Infection · doi:10.1007/s15010-009-8450-7 · Cited by 94
“vere oxidative and nitrosative stress, and shuts off active replication but increases cell-wall thickness [8].”
BackgroundWhat is the role of Toll-like receptors in bacterial infections?
Gerold, G., Zychlinsky, A., & de Diego, J. L. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2006.12.003 · Cited by 91
Delamanid or pretomanid? A Solomonic judgement!
Mudde, S. E., Upton, A. M., Lenaerts, A. J. M., Bax, H. I., & de Steenwinkel, J. E. M. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab505 · Cited by 85
Tuberculosis in the age of biologic therapy
Hernandez, C., Cetner, A. S., Jordan, J., Puangsuvan, S. N., & Robinson, J. K. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.05.033 · Cited by 78
“It has no known animal reservoirs and a slow replication time of approximately 12 hours, as compared to 30 minutes for most other bacteria.(4) Mycobacterium species, including M tuberculosis, are distinguished histologically by their ‘‘acid-fast’’ staining.”
BackgroundRecent findings in immunology give tuberculosis vaccines a new boost
Kaufmann, S. H. E. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.09.012 · Cited by 92
Mycobacterium tuberculosis Ser/Thr Protein Kinase B Mediates an Oxygen-Dependent Replication Switch
Ortega, C., Liao, R., Anderson, L. N., Rustad, T., Ollodart, A. R., Wright, A. T., Sherman, D. R., & Grundner, C. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001746 · Cited by 74
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent
Arai, M., Sobou, M., Vilchèze, C., Baughn, A. D., Hashizume, H., Pruksakorn, P., Ishida, S., Matsumoto, M., Jacobs, W. R., & Kobayashi, M. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.05.061 · Cited by 79
Small, J. L., Park, S. W., Kana, B. D., Ioerger, T. R., Sacchettini, J. C., & Ehrt, S. (2013) · mBio · doi:10.1128/mbio.00475-13 · Cited by 78
Lipidomics of host–pathogen interactions
Wenk, M. R. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.07.007 · Cited by 74
“the details of metabolically inactive conditions in particular under conditions which reflect the environment in vivo [78,79].”
BackgroundBhat, S. A., Iqbal, I. K., & Kumar, A. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00145 · Cited by 85
“Mtb employs alternative and parallel metabolic pathways for in vivo survival, wherein it faces stresses such as limiting carbon sources, hypoxia, variable pH, reactive oxygen species, reactive nitrogen species, etc. (Pieters and Gatfield, 2002; Boshoff and Barry, 2005; Gleeson et al., 2016).”
BackgroundPienaar, E., Cilfone, N. A., Lin, P. L., Dartois, V. A., Mattila, J. T., Butler, J. R., Flynn, J. L., Kirschner, D. E., & Linderman, J. J. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.11.021 · Cited by 74
“However, low levels of metabolic activity remain in these bacteria[40], and therefore we assign a slow growth rate to this sub-population in the model (100-fold lower than B E ).”
BackgroundNovel tuberculosis vaccines on the horizon
Parida, S. K., & Kaufmann, S. H. E. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.006 · Cited by 77
Interaction betweenBurkholderia pseudomalleiand the Host Immune Response: Sleeping with the Enemy?
Gan, Y. (2005) · The Journal of Infectious Diseases · doi:10.1086/497382 · Cited by 84
Mogi, T., Murase, Y., Mori, M., Shiomi, K., Ōmura, S., Paranagama, M. P., & Kita, K. (2009) · The Journal of Biochemistry · doi:10.1093/jb/mvp096 · Cited by 71
Drug development against tuberculosis: Impact of alkaloids
Mishra, S. K., Tripathi, G., Kishore, N., Singh, R. K., Singh, A. K., & Tiwari, V. K. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.005 · Cited by 72
PE_PGRS proteins are differentially expressed by Mycobacterium tuberculosis in host tissues
Delogu, G., Sanguinetti, M., Pusceddu, C., Bua, A., Brennan, M. J., Zanetti, S., & Fadda, G. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.03.015 · Cited by 67
Farhana, A., Guidry, L., Ak, S., Singh, A., Hondalus, M. K., & Steyn, A. J. C. (2010) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/b978-0-12-381045-8.00002-3 · Cited by 69
Pieroni, M., Wan, B., Cho, S., Franzblau, S. G., & Costantino, G. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.11.007 · Cited by 66
Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery
Iqbal, I., Bajeli, S., Akela, A. K., & Kumar, A. (2018) · Pathogens · doi:10.3390/pathogens7010024 · Cited by 68
“Mycobacteria possess a branched ETC.”
BackgroundInfluentialPieroni, M., Tipparaju, S. K., Lun, S., Song, Y., Sturm, A. W., Bishai, W. R., & Kozikowski, A. P. (2011) · ChemMedChem · doi:10.1002/cmdc.201000490 · Cited by 72
Modeling Phenotypic Metabolic Adaptations of Mycobacterium tuberculosis H37Rv under Hypoxia
Fang, X. D., Wallqvist, A., & Reifman, J. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002688 · Cited by 68
“tuberculosis to hypoxia [16,52] and could serve as a drug target for the elimination of this pathogen in latent disease states.”
BackgroundJain, N., Kalam, H., Singh, L., Sharma, V., Kedia, S., Das, P., Ahuja, V., & Kumar, D. (2020) · Nature Communications · doi:10.1038/s41467-020-16877-3 · Cited by 65
The Transcriptional Regulatory Network of Mycobacterium tuberculosis
Sanz, J., Navarro, J., Arbués, A., Martín, C., Marijuán, P. C., & Moreno, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022178 · Cited by 72
“The bacillus switches metabolic pathways to utilize fatty acids rather than carbohydrates during infection [5].”
BackgroundGlucose 6-Phosphate Accumulation in Mycobacteria
Hasan, M. R., Rahman, M., Jaques, S., Purwantini, E., & Daniels, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.074310 · Cited by 64
Rapid metabolic analysis of Rhodococcus opacus PD630 via parallel 13C‐metabolite fingerprinting
Hollinshead, W. D., Henson, W. R., Abernathy, M. H., Moon, T. S., & Tang, Y. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25702 · Cited by 70
Mycobacterium Tuberculosis Metabolism and Host Interaction: Mysteries and Paradoxes
Ehrt, S., & Rhee, K. Y. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_299 · Cited by 78
“…reported by in situ staining with pimonidazole, and presumptive gradients of other blood borne nutrients, that culminate in necrosis, a central caseation that is sometimes surrounded by calcification, and accumulation of extracellular bacilli (Boshoff and Barry 2005; Russell 2006; Via et al. 2008).”
BackgroundAutofluorescence of Mycobacteria as a Tool for Detection of Mycobacterium tuberculosis
Patiño, S., Alamo, L., Cimino, M., Casart, Y., Bartoli, F., García, M. J., & Salazar, L. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02183-07 · Cited by 59
Verma, R., Pinto, S. M., Patil, A. H., Advani, J., Subba, P., Kumar, M., Sharma, J. N., Dey, G., Ravikumar, R., Buggi, S., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00983 · Cited by 65
Zheng, Y., Jiang, X., Gao, F., Song, J.-X., Sun, J., Wang, L., Sun, X., Lu, Z., & Zhang, H. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-400 · Cited by 63
“The human immune system and classical antibacterial agents have the capacity to destroy Mtb in the proliferating state but not in the nonreplicating “drug tolerant” or “phenotypically drug resistant” state [5-7].”
BackgroundAnand, A., Verma, P., Singh, A. K., Kaushik, S., Pandey, R., Shi, C., Kaur, H., Chawla, M., Elechalawar, C. K., Kumar, D., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.016 · Cited by 62
“Among the many challenging conditions, differential oxygen levels can elicit comprehensive changes in mycobacterial physiology (Barry et al., 2009; Boshoff and Barry, 2005).”
Regulation of nitrate reductase activity in Mycobacterium tuberculosis by oxygen and nitric oxide
Sohaskey, C. D. (2005) · Microbiology · doi:10.1099/mic.0.28263-0 · Cited by 60
“It has been suggested that oxygen limitation may be the important signal for NRP in humans, but in mice it may be NO (Boshoff & Barry, 2005).”
BackgroundSiricilla, S., Mitachi, K., Wan, B., Franzblau, S. G., & Kurosu, M. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.133 · Cited by 60
In Vitro Pharmacokinetic/Pharmacodynamic Models in Anti-Infective Drug Development: Focus on TB
Vaddady, P. K., Lee, R. E., Jr., & Meibohm, B. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.224 · Cited by 68
“Although animal models can provide similar growing conditions for bacteria as the human host and thus imitate the characteristics of a human infection, the potential differences in PK such as rate and extent of drug metabolism and in drug delivery to the species-specific tubercular lesions, such as to organized granul…”
BackgroundPhthiocerol Dimycocerosate Transport Is Required for Resisting Interferon‐γ–Independent Immunity
Murry, J. P., Pandey, A. K., Sassetti, C. M., & Rubin, E. J. (2009) · The Journal of Infectious Diseases · doi:10.1086/605128 · Cited by 68
“constant threat to host survival [3].”
Lilienkampf, A., Pieroni, M., Wan, B., Wang, Y., Franzblau, S. G., & Kozikowski, A. P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901273n · Cited by 65
Li, Z., & Velkov, T. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16373-0_4 · Cited by 69
Developments on Drug Delivery Systems for the Treatment of Mycobacterial Infections
Gaspar, M. M., Cruz, A., Fraga, A. G., Castro, A. G., Cruz, M. E. M., & Pedrosa, J. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783955629 · Cited by 61
Benzimidazole-based compounds kill Mycobacterium tuberculosis
Gong, Y., Somersan-Karakaya, S., Guo, X., Zheng, P., Gold, B. S., Ma, Y., Little, D., Roberts, J., Warrier, T., Jiang, X., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.039 · Cited by 61
Mycobacterium tuberculosis Metabolism
Mashabela, G. T., de Wet, T. J., & Warner, D. F. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0067-2019 · Cited by 71
Unconventional screening approaches for antibiotic discovery
Farha, M. A., & Brown, E. D. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12803 · Cited by 60
Saini, V., Farhana, A., & Steyn, A. J. C. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4341 · Cited by 62
Histoplasma capsulatum Depends on De Novo Vitamin Biosynthesis for Intraphagosomal Proliferation
Garfoot, A. L., Zemska, O., & Rappleye, C. A. (2013) · Infection and Immunity · doi:10.1128/iai.00824-13 · Cited by 60
Phong, W. Y., Lin, W., Rao, S. P. S., Dick, T., Alonso, S., & Pethe, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056037 · Cited by 56
“tuberculosis, the etiological agent of TB, represents one of the key virulence strategies developed by the pathogen to persist in many microenvironments within its host [2].”
BackgroundA philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis
Nathan, C., Gold, B. S., Lin, G., Stegman, M. A., de Carvalho, L. P. S., Vandal, O. H., Venugopal, A., & Bryk, R. (2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70034-9 · Cited by 57
Moosa, A., Lamprecht, D. A., Arora, K., Barry, C. E., Boshoff, H. I., Ioerger, T. R., Steyn, A. J. C., Mizrahi, V., & Warner, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01338-17 · Cited by 58
Self-citationFoo, C. S.-Y., Pethe, K., & Lupien, A. (2020) · Applied Sciences · doi:10.3390/app10072339 · Cited by 61
Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis
Hasenoehrl, E., Wiggins, T. J., & Berney, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.611683 · Cited by 61
Molecular Insights into the Biosynthesis of the F420 Coenzyme
Forouhar, F., Abashidze, M., Xu, H., Grochowski, L. L., Seetharaman, J., Hussain, M., Kuzin, A. P., Yang, C., Zhou, W., Xiao, R., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710352200 · Cited by 55
Micklinghoff, J. C., Breitinger, K. J., Schmidt, M., Geffers, R., Eikmanns, B. J., & Bange, F. (2009) · Journal of Bacteriology · doi:10.1128/jb.01009-09 · Cited by 53
“tuberculosis subsists mainly on fatty acids rather than on carbohydrates within the host (6, 30).”
BackgroundMycobacterial genes essential for the pathogen's survival in the host
Ehrt, S., Rhee, K. Y., & Schnappinger, D. (2015) · Immunological Reviews · doi:10.1111/imr.12256 · Cited by 60
New Targets and Inhibitors of Mycobacterial Sulfur Metabolism
Paritala, H., & Carroll, K. S. (2013) · Infectious Disorders - Drug Targets · doi:10.2174/18715265113139990022 · Cited by 54
“In the rest, mycobacteria residing within granulomas enter into a persistent or “latent” state characterized by a lack of cell division and a change in basic metabolism [33, 34].”
BackgroundKundu, M., & Basu, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.642487 · Cited by 57
Arora, D., Chawla, Y., Malakar, B., Singh, A., & Nandicoori, V. K. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.811190 · Cited by 48
“Mycobacterium tuberculosis (Mtb) cell wall is a complex structure that provides osmotic stability, drug resistance, enhanced virulence(1-3) and protects it from stress conditions in the host, such as reactive oxygen species (ROS), starvation, and hypoxia(4-9).”
The TB Structural Genomics Consortium: A decade of progress
Chim, N., Habel, J. E., Johnston, J. M., Krieger, I. V., Miallau, L., Sankaranarayanan, R. K., Morse, R. P., Bruning, J. B., Swanson, S., Kim, H., et al. (2011) · Tuberculosis · doi:10.1016/j.tube.2010.11.009 · Cited by 56
Lockwood, S. Y., Meisel, J. E., Monsma, F. J., & Spence, D. M. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04270 · Cited by 49
Evangelopoulos, D., da Fonseca, J. D., & Waddell, S. J. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.11.028 · Cited by 53
Central Role of Pyruvate Kinase in Carbon Co-catabolism of Mycobacterium tuberculosis
Noy, T., Vergnolle, O., Hartman, T. E., Rhee, K. Y., Jacobs, W. R., Berney, M., & Blanchard, J. S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.707430 · Cited by 51
“This cannot be achieved when the culture is supplemented with acetate, because it enters the TCA cycle through AcCoA, and requires NAD for its catabolism (51, 52).”
BackgroundGutierrez-Lugo, M.-T., Baker, H., Shiloach, J., Boshoff, H., & Bewley, C. A. (2009) · SLAS Discovery · doi:10.1177/1087057109335743 · Cited by 49
Self-citationKalia, N. P., Singh, S., Hards, K., Cheung, C., Sviriaeva, E. N., Banaei‐Esfahani, A., Aebersold, R. H., Berney, M., Cook, G. M., & Pethe, K. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112444 · Cited by 51
Distribution and dynamics of OXPHOS complexes in the bacterial cytoplasmic membrane
Magalon, A., & Alberge, F. (2015) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2015.10.015 · Cited by 50
In vitro drug discovery models for Mycobacterium tuberculosis relevant for host infection
Parish, T. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1707801 · Cited by 49
“Active disease with symptoms implies rapid replication, but the fact that >4 months of treatment with multiple drugs is required for a durable cure (>2 years without relapse) is attributed to the existence of populations of non-replicating bacteria [14].”
BackgroundTuberculous Granuloma: Emerging Insights From Proteomics and Metabolomics
Sholeye, A. R., Williams, A. A., Loots, D. T., van Furth, A. M., van der Kuip, M., & Mason, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.804838 · Cited by 51
“Under aerobic conditions, the bacilli are predicted to access glucose and triacylglycerides as sources of carbon throughout early replication; however, glucose-deficient macrophages trigger a metabolic shift in Mtb to utilize lipids (72, 121).”
BackgroundPieroni, M., Lilienkampf, A., Wan, B., Wang, Y., Franzblau, S. G., & Kozikowski, A. P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900513a · Cited by 46
Inhibition of Mycobacterial Growth by Plumbagin Derivatives
Mathew, R., Kruthiventi, A. K., Prasad, J. V., Kumar, S. P., Srinu, G., & Chatterji, D. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.00987.x · Cited by 45
“Among these, the pathways for electron transport and respiration are involved in both latent and rapidly growing mycobacteria (3).”
BackgroundSiccanin Rediscovered as a Species-Selective Succinate Dehydrogenase Inhibitor
Mogi, T., Kawakami, T., Arai, H., Igarashi, Y., Matsushita, K., Mori, M., Shiomi, K., Ōmura, S., Harada, S., & Kita, K. (2009) · The Journal of Biochemistry · doi:10.1093/jb/mvp085 · Cited by 45
Aljayyoussi, G., Jenkins, V. A., Sharma, R., Ardrey, A., Donnellan, S., Ward, S. A., & Biagini, G. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00529-6 · Cited by 44
Clonal Expansion of CD8+ Effector T Cells in Childhood Tuberculosis
Jacobsen, M., Detjen, A., Mueller, H., Gutschmidt, A., Schommer-Leitner, S., Wahn, U., Magdorf, K., & Kaufmann, S. H. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.1331 · Cited by 44
Giffin, M. M., Shi, L., Gennaro, M. L., & Sohaskey, C. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155522 · Cited by 45
“The different expression pattern of ald during in vivo infection in comparison to that of in vitromodels may reflect the lack of hypoxia in infected mouse lungs [2,3].”
BackgroundKasbekar, M., Fischer, G., Mott, B. T., Yasgar, A., Hyvönen, M., Boshoff, H. I., Abell, C., Barry, C. E., & Thomas, C. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600630113 · Cited by 47
“Fumarate (1) is used to initiate the reaction, and (L)-malate (2), oxaloacetate (3), and citrate (4) are produced.”
BackgroundSelf-citationDhameliya, T. M., Bhakhar, K. A., Gajjar, N. D., Patel, K. A., Devani, A. A., & Hirani, R. V. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131473 · Cited by 43
Tang, Y., Shui, W., Myers, S. A., Feng, X., Bertozzi, C. R., & Keasling, J. D. (2009) · Biotechnology Letters · doi:10.1007/s10529-009-9991-7 · Cited by 50
Agarwal, P., Khan, S. R., Verma, S. C., Beg, M., Singh, K., Mitra, K., Gaikwad, A. N., Akhtar, M. S., & Krishnan, M. Y. (2014) · Microbes and Infection · doi:10.1016/j.micinf.2014.04.006 · Cited by 46
Lewis, A. H., & Falkinham, J. O. (2015) · International Journal of Mycobacteriology · doi:10.1016/j.ijmyco.2014.11.066 · Cited by 43
Tuberculosis Drugs: New Candidates and How to Find More
Sala, C., & Hartkoorn, R. C. (2011) · Future Microbiology · doi:10.2217/fmb.11.46 · Cited by 48
The Physiology and Genetics of Oxidative Stress in Mycobacteria
Cumming, B. M., Lamprecht, D. A., Wells, R. M., Saini, V., Mazorodze, J. H., & Steyn, A. J. C. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0019-2013 · Cited by 38
Li, X., Liu, N., Zhang, H., Knudson, S. E., Li, H., Lai, C., Simmerling, C. L., Slayden, R. A., & Tonge, P. J. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200141e · Cited by 41
Mohanty, S., Jagannathan, L., Ganguli, G., Padhi, A., Roy, D., Alaridah, N., Saha, P., Nongthomba, U., Godaly, G., Gopal, R. K., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.598482 · Cited by 41
“Although the metabolism required for sustaining mycobacterial survival during latency is still poorly understood, experimental evidence has suggested the essentiality of nucleotide synthesis in latent bacilli (92).”
BackgroundDrain, P. K., Gounder, L., Grobler, A. C., Sahid, F., Bassett, I. V., & Moosa, M. S. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006833 · Cited by 41
Abhale, Y. K., Sasane, A. V., Chavan, A., Deshmukh, K. K., Kotapalli, S. S., Ummanni, R., Sayyad, S. F., & Mhaske, P. C. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.016 · Cited by 41
Lipid Metabolism and Intracellular Bacterial Virulence: key to Next-Generation Therapeutics
Rameshwaram, N. R., Singh, P., Ghosh, S., & Mukhopadhyay, S. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0013 · Cited by 45
Mycofactocin Is Associated with Ethanol Metabolism in Mycobacteria
Gopinath, K., Kaiser, P., Lozza, L., Hahnke, K., Mollenkopf, H., & Kaufmann, S. H. E. (2019) · mBio · doi:10.1128/mbio.00190-19 · Cited by 40
“Mycobacterial respiration under hostile conditions requires utilization of different electron donors and acceptors, the diversity of which is not completely known (19, 41).”
Background
Metadata
- Authors
- Boshoff, H. I. M., & Barry, C. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Boshoff, Helena I. M.
- Venue
- Nature Reviews Microbiology
- Published
- 2005-01
- Volume
- 3
- Issue
- 1
- Pages
- 70-80
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1973789730
- Cited by
- 448
- References
- 88
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 11 · 2023: 11 · 2022: 9 · 2021: 17 · 2020: 20 · 2019: 22 · 2018: 21 · 2017: 22 · 2016: 20 · 2015: 35 · 2014: 30 · 2013: 24 · 2012: 26
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (Z01AI000783)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tuberculosis, Mycobacterium tuberculosis, bacterial metabolism, respiration, non-replicating persistence, animal models of tuberculosis, transcriptomics, bacterial mutants, reducing equivalents, membrane potential, bacterial viability
- MeSH terms
- Adaptation, Physiological, Animals, Citric Acid Cycle, Gluconeogenesis, Humans, Mycobacterium tuberculosis, Oxidation-Reduction, Oxygen Consumption, Riboflavin, Tuberculosis, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.